ArticleScientific reports2026
The coexistence of MAFLD increases fibrosis burden in patients with chronic hepatitis B.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic Accuracy of Serum-Based Fibrosis Scores for Clinically Significant Liver Fibrosis in an East Asian Cohort.The Kaohsiung journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the increasing recognition of metabolic dysfunction-associated fatty liver disease (MAFLD) and Chronic Hepatitis B (CHB), their interplay on liver fibrosis remains insufficiently elucidated. This study aimed to assess liver fibrosis in CHB patients with concurrent MAFLD. This cross-sectional study included 148 patients with a confirmed diagnosis of CHB infection, categorized according to the MAFLD standard criteria into CHB with MAFLD (CHB/+MAFLD) and without MAFLD (CHB/-MAFLD). Demographic, metabolic, and biochemical parameters were analyzed. Fibrosis was assessed non-invasively using vibration-controlled transient elastography (VCTE). A multivariate logistic regression identified independent predictors of significant fibrosis. Among the CHB cohort, 34.5% fulfilled MAFLD criteria. Using FIB-4 > 1.3 for significant fibrosis, the CHB/+MAFLD group exhibited a higher prevalence of significant fibrosis 45.1% vs. 23.7% in the CHB/-MAFLD group, with higher medians in the CHB/+MAFLD group (1.2 vs. 0.8, p < 0.001). Using liver stiffness measurement (LSM), those with MAFLD had a higher prevalence of significant fibrosis (F ≥ 2; 37.3 vs. 16.5%, p 0.005) than in those without MAFLD (medians 6.1 and 5.6 kPa, respectively, p 0.03). In multivariate analysis, MAFLD independently increased the odds of significant fibrosis (4.48, 95% CI 1.29-15.6, p 0.019) in CHB patients. The interplay of MAFLD and CHB is associated with worsening liver injury and fibrosis progression. Given the high prevalence of MAFLD and negative impact, metabolic risk assessment should be incorporated into routine CHB care to reduce fibrosis and improve long-term liver outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.